Cargando…

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active...

Descripción completa

Detalles Bibliográficos
Autores principales: Velpurisiva, Praveena, Piel, Brandon P., Lepine, Jack, Rai, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315921/
https://www.ncbi.nlm.nih.gov/pubmed/30304810
http://dx.doi.org/10.3390/bioengineering5040083
_version_ 1783384408228626432
author Velpurisiva, Praveena
Piel, Brandon P.
Lepine, Jack
Rai, Prakash
author_facet Velpurisiva, Praveena
Piel, Brandon P.
Lepine, Jack
Rai, Prakash
author_sort Velpurisiva, Praveena
collection PubMed
description Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications.
format Online
Article
Text
id pubmed-6315921
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63159212019-01-10 GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM) Velpurisiva, Praveena Piel, Brandon P. Lepine, Jack Rai, Prakash Bioengineering (Basel) Article Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications. MDPI 2018-10-09 /pmc/articles/PMC6315921/ /pubmed/30304810 http://dx.doi.org/10.3390/bioengineering5040083 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Velpurisiva, Praveena
Piel, Brandon P.
Lepine, Jack
Rai, Prakash
GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title_full GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title_fullStr GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title_full_unstemmed GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title_short GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)
title_sort gsk461364a, a polo-like kinase-1 inhibitor encapsulated in polymeric nanoparticles for the treatment of glioblastoma multiforme (gbm)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315921/
https://www.ncbi.nlm.nih.gov/pubmed/30304810
http://dx.doi.org/10.3390/bioengineering5040083
work_keys_str_mv AT velpurisivapraveena gsk461364aapololikekinase1inhibitorencapsulatedinpolymericnanoparticlesforthetreatmentofglioblastomamultiformegbm
AT pielbrandonp gsk461364aapololikekinase1inhibitorencapsulatedinpolymericnanoparticlesforthetreatmentofglioblastomamultiformegbm
AT lepinejack gsk461364aapololikekinase1inhibitorencapsulatedinpolymericnanoparticlesforthetreatmentofglioblastomamultiformegbm
AT raiprakash gsk461364aapololikekinase1inhibitorencapsulatedinpolymericnanoparticlesforthetreatmentofglioblastomamultiformegbm